Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Rahul Aggarwal, MD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1600 Divisadero
    San Francisco CA 94115
    Phone415-353-9278
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoResidency School of Medicine - Internal Medicine
      Northwestern University FeinbergM.D.School of Medicine2006

      Collapse ORNG Applications 
      Collapse Clinical Trials
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL, et al. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Jul 25. PMID: 27453303.
        View in: PubMed
      2. Aggarwal R. Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure? Eur Urol. 2016 Sep; 70(3):445-6. PMID: 26992281.
        View in: PubMed
      3. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 Aug; 34(8):368-74. PMID: 26944450.
        View in: PubMed
      4. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. PMID: 26603258.
        View in: PubMed
      5. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1. PMID: 25783510.
        View in: PubMed
      6. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. PMID: 25557266.
        View in: PubMed
      7. Aggarwal RR, Small EJ. Small-cell/neuroendocrine prostate cancer: a growing threat? Oncology (Williston Park). 2014 Oct; 28(10):838-40. PMID: 25323608.
        View in: PubMed
      8. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65. PMID: 24934865.
        View in: PubMed
      9. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014 May; 12(5):719-26. PMID: 24812138.
        View in: PubMed
      10. Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct; 12(5):e167-72. PMID: 24787968.
        View in: PubMed
      11. Aggarwal R, Kurhanewicz J. The changing role of imaging in clinical care. Nat Rev Urol. 2014 Feb; 11(2):75-7. PMID: 24418808; PMCID: PMC4057014.
      12. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43. PMID: 23913744; PMCID: PMC3795898.
      13. Aggarwal RR, Ryan CJ, Chan JM. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol. 2013 Jul; 31(5):522-30. PMID: 21658978.
        View in: PubMed
      14. Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011; 16(3):264-75. PMID: 21339259; PMCID: PMC3228103.
      15. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. PMID: 19815485.
        View in: PubMed
      Rahul's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP